Evidence Behind the Use of Nandrolone in TRT Protocols to Mitigate Side Effects and Reduce Joint Pain.
While testosterone is considered an anabolic androgenic steroid, it has not been saddled with the social stigma that other, similar medications have, such as: Nandrolone, stanozolol, oxandrolone, and methenolone. With the increasing rise in incidence of male hypogonadism, and the growing knowledge of the roles for testosterone in male health, other pharmacological steroid compounds should be evaluated to either supplement, and/or replace testosterone in the treatment of male health.
Unfortunately, numerous well-published media reports dealing with anabolic steroids in professional and Olympic athletes have brought a cloud of speculation and doubt regarding use of these “illicit” medications. The fact that these anabolic steroid medications are banned by numerous athletic associations such as the International Olympic Committee as well as the National Football and Basketball Associations and Major League Baseball, further re-enforces the public perception that these medications should not be used under any circumstances. These perceptions were enhanced by the passage of the Anabolic Steroid Control Act of 2004 that listed anabolic steroids as schedule III-controlled substances—similar to ketamine, opiates and morphine. This policy mandated that a physician prescription was necessary to obtain the medication; further challenging the opinion of the general public. As such, it is tempting to speculate that investigations into alternatives to testosterone therapy have been slowed by societal stigma and perception.
Nandrolone is a hormone that bears similarity in chemical appearance to testosterone. The only major difference between the two molecules is a single methyl group. Nandrolone has a higher greater binding affinity to androgen receptors with reduced androgenic activity.
Many adverse side effects of testosterone are caused by its conversion to estrogen. Although nandrolone also undergoes aromatization into estradiol, it aromatizes at a rate of only about 20% of that of testosterone or possibly even less; one study found virtually no aromatization of nandrolone in men. Therefore, careful blending of testosterone with nandrolone can mitigate adverse estrogenic side effects.
Additionally, many adverse side effects of testosterone are caused by the actions of 5 alpha reductase on testosterone producing Dihydrotestosterone (DHT). DHT binds to androgen receptors in the hair follicles, which, for some people, can cause alopecia (hair loss). Additionally, DHT binds to androgen receptors in the prostate, which, for some people, can cause benign prostate hyperplasia (enlarged prostate). Nandrolone is reduced by 5 alpha reductase into dihydronandrolone (DNT), which has a significantly lower binding affinity to the androgen receptor. Therefore, careful blending of testosterone with nandrolone can mitigate adverse side effects caused by DHT.
Furthermore, for decades, nandrolone has purported and been evangelized by countless users to significantly reduce joint pain. Although limited data exists, anecdotal and empirical evidence has been used to suggest that nandrolone may reduce inflammation of tendons, and increase synovial fluid production in the joints, mitigating problems in these areas. Therefore, utilizing nandrolone in your TRT regimen may reduce joint and tendon pain.
Years of unwarranted stigma have caused the medical community to ignore the potential benefits of this extraordinary compound. Hormonesforme.com and Hormonizehealth.com has over 20 years’ experience blending testosterone with nandrolone, and other beneficial compounds, to mitigate side effects and optimize the way people look and feel. If you experience estrogenic side effects, or joint pain, consider utilizing nandrolone in your next TRT protocol.
1. Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Transl Androl Urol. 2016;5(2):213-219. doi:10.21037/tau.2016.03.03
2. Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 402–412, 193–194. ISBN 978-0-9828280-1-4.
3. Partha Sardar, Ayan Jha, Deeptarka Roy, Uddalak Majumdar, Pradipta Guha, Sabyasachi Roy, Ramtanu Banerjee, Amit Kumar Banerjee & Dipanjan Bandyopadhyay (2010) Therapeutic Effects of Nandrolone and Testosterone in Adult Male HIV Patients With AIDS Wasting Syndrome (AWS): A Randomized, Double-Blind, Placebo-Controlled Trial, HIV Clinical Trials, 11:4, 220-229, DOI: 10.1310/hct1104-220